Emily Field is ranked #1056 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Emily Field (Barclays) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Emily Field's stock ratings?

About 53% of Emily's ratings were profitable over a one-year hold, with an average return of +1.7% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Emily Field

BARC

Emily Field

Barclays

Wall Street Analyst

★★★☆☆

#1056

on 13Foresight · ranked by our own returns

53%

Success Rate

+1.7%

Average Return

16 of 30 calls profitable · -0.7% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 53% of Emily Field's ratings turned a profit when each position was held for 1 year — averaging +1.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

49 Buy 23 Hold 9 Sell

Emily's Stock Coverage 33 ratings · 2026-07-15

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
LLY Eli Lilly & Co	Jul 13, 2026	BUY	Strong Buy -10.6% avg upside 47 analysts	$1400.00 18.38% Upside	+0.0%
ABBV AbbVie	Jun 26, 2026	BUY	Strong Buy -4.5% avg upside 46 analysts	$275.00 10.86% Upside	-3.6%
MRK Merck & Company	Jun 26, 2026	BUY	Strong Buy +6.5% avg upside 43 analysts	$140.00 12.95% Upside	-6.2%
PFE Pfizer	Jun 15, 2026	SELL	Buy +37.9% avg upside 45 analysts	$25.00 2.04% Upside	+6.7%
BMY Bristol-Myers Squibb	Jun 02, 2026	BUY	Buy +2.4% avg upside 42 analysts	$75.00 26.29% Upside	+5.8%
BIIB Biogen	May 14, 2026	HOLD	Strong Buy +27.2% avg upside 52 analysts	$185.00 11.55% Downside	+3.1%
AMGN Amgen	May 05, 2026	HOLD	Buy -16.1% avg upside 57 analysts	$350.00 2.84% Downside	+8.6%
GILD Gilead Sciences	Apr 21, 2026	HOLD	Strong Buy -8.5% avg upside 66 analysts	$155.00 18.04% Upside	-0.8%
CYTK Cytokinetics	Apr 06, 2026	BUY	Strong Buy +7.2% avg upside 36 analysts	$95.00 15.59% Upside	+30.7%
GSK GlaxoSmithKline	Jan 06, 2026	SELL	Buy -14.9% avg upside 19 analysts	—	-5.2%
RHHBY Roche Holding	Jan 06, 2026	BUY	Buy -0.8% avg upside 14 analysts	—	+2.4%
SNY Sanofi	Jan 06, 2026	HOLD	Strong Buy +69.7% avg upside 20 analysts	—	-4.3%
NVS Novartis	Jan 06, 2026	HOLD	Buy -10.1% avg upside 24 analysts	—	+8.9%
CH:ROP Roche Holding AG	Sep 24, 2025	HOLD	Buy +1.5% avg upside 23 analysts	$275.00 16.78% Downside	·
FR:SAN Sanofi	Aug 12, 2025	BUY	Strong Buy +29.8% avg upside 30 analysts	$105.00 36.14% Upside	·
GB:GSK GlaxoSmithKline	Aug 12, 2025	HOLD	Hold -1.5% avg upside 25 analysts	$1450.00 25.85% Downside	·
CH:SDZ Sandoz Group Ltd	Aug 08, 2025	BUY	Buy +1.6% avg upside 11 analysts	$55.00 17.57% Downside	·
GB:0QIU Novo Nordisk	Aug 04, 2025	HOLD	Buy +27.1% avg upside 29 analysts	$375.00 16.61% Upside	·
GB:AZN AstraZeneca	Jul 30, 2025	BUY	Strong Buy +18.8% avg upside 26 analysts	$14000.00 11.02% Upside	·
NL:LKFT Galapagos	Jul 29, 2025	SELL	Sell +103.2% avg upside 16 analysts	$22.00 16.39% Downside	·
CH:NOVN Novartis AG	Jul 21, 2025	SELL	Buy -12.6% avg upside 31 analysts	$90.00 27.73% Downside	·
DE:BAYN Bayer	Jun 27, 2025	HOLD	Strong Buy +5.9% avg upside 28 analysts	$25.00 49.88% Downside	·
GB:HIK Hikma Pharmaceuticals	Apr 25, 2025	HOLD	Strong Buy +54.8% avg upside 8 analysts	$2000.00 27.08% Upside	·
GB:0MGB Genmab A/S	Apr 15, 2025	BUY	Buy +15.2% avg upside 22 analysts	$2100.00 11.04% Upside	·
DE:MRK Merck KGaA	Oct 29, 2024	BUY	Buy -2.5% avg upside 33 analysts	$195.00 39.52% Upside	·
GB:0QW0 arGEN X	Jun 21, 2023	BUY	Strong Buy -21.9% avg upside 24 analysts	$430.00 46.03% Downside	·
ES:GRF Grifols	Nov 21, 2022	SELL	Buy +66.5% avg upside 12 analysts	$9.00 0.97% Upside	·
FR:IPN Ipsen	Nov 25, 2021	SELL	Buy -22.8% avg upside 17 analysts	$75.00 53.34% Downside	·
GB:0NZT UCB SA	Oct 15, 2021	HOLD	Strong Buy -4.8% avg upside 19 analysts	$90.00 63.50% Downside	·
LKFT Lakefront Biotherapeutics	Jan 19, 2021	HOLD	Buy +258.4% avg upside 24 analysts	$125.00 319.47% Upside	·
HK:0013 HUTCHMED (China)	Aug 28, 2020	HOLD	Buy +548.6% avg upside 6 analysts	$52.44 196.65% Upside	·
RVLPQ RVL Pharmaceuticals	Apr 25, 2019	BUY	Strong Buy +624999900.0% avg upside 6 analysts	$14.00 1399999900.01% Upside	-6.8%
GRFS Grifols SA	Jun 01, 2018	BUY	Buy +253.3% avg upside 12 analysts	$33.05 359.12% Upside	-19.0%

🔒 28 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Emily Field — Frequently Asked Questions

How accurate are Emily Field's stock ratings?

Based on the calls 13Foresight could measure, about 53% of Emily's ratings were profitable over a one-year hold, with an average return of +1.7% per rating, or -0.7% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Emily ranked on 13Foresight?

Emily Field is currently ranked #1056 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Emily cover?

Emily most recently has ratings on LLY, ABBV, MRK, PFE, BMY, BIIB, AMGN, GILD, CYTK, GSK, RHHBY, SNY and 21 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!